Risk adjusted net present value: What is the current valuation of Rallybio’s RLYB-116?
RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I program in Myasthenia Gravis. According to Globaldata, …
Post
-
-
Risk adjusted net present value: What is the current valuation of ORIC Pharmaceuticals’s ORIC-944?
ORIC-944 is a small molecule commercialized by ORIC Pharmaceuticals, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer …
-
Risk adjusted net present value: What is the current valuation of Plus Therapeutics’s Rhenium (186Re) Obisbemeda?
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Recurrent Glioblastoma …
-
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Imlunestrant tosylate?
Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Metastatic …
-
Risk adjusted net present value: What is the current valuation of Adicet Bio’s ADI-001?
ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in Lupus Nephritis. According …
-
Risk adjusted net present value: What is the current valuation of Adicet Bio’s ADI-001?
ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in Lupus Nephritis. According …
-
Risk adjusted net present value: What is the current valuation of Novartis’s Rapcabtagene autoleucel?
Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Diffuse Large B-Cell …
-
Flu vaccine strategy on the line as new US leaders anticipated to take charge
As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due …
-
Risk adjusted net present value: What is the current valuation of I-Mab’s Lemzoparlimab?
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Solid Tumor. According to Globaldata, …
-
Risk adjusted net present value: What is the current valuation of Pfizer’s (Clesacostat tromethamine + Ervogastat)?
(Clesacostat tromethamine + Ervogastat) is a small molecule commercialized by Pfizer, with a leading Phase II program in Metabolic Dysfunction-Associated …
-
Risk adjusted net present value: What is the current valuation of Vertex Pharmaceuticals’s Inaxaplin?
Inaxaplin is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Phase III program in Focal Segmental Glomerulosclerosis (FSGS). …
-
Risk adjusted net present value: What is the current valuation of I-Mab’s Uliledlimab?
Uliledlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Ovarian Cancer. According to Globaldata, …
-
Risk adjusted net present value: What is the current valuation of Vaxart’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine?
Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine is a recombinant vector vaccine commercialized by Vaxart, with a leading …
-
Risk adjusted net present value: What is the current valuation of 89bio’s Pegozafermin?
Pegozafermin is a recombinant protein commercialized by 89bio, with a leading Phase III program in Fibrosis. According to Globaldata, it …
-
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Peresolimab?
Peresolimab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Autoimmune Disorders. …